BG108253A - ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I - Google Patents

ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I Download PDF

Info

Publication number
BG108253A
BG108253A BG108253A BG10825303A BG108253A BG 108253 A BG108253 A BG 108253A BG 108253 A BG108253 A BG 108253A BG 10825303 A BG10825303 A BG 10825303A BG 108253 A BG108253 A BG 108253A
Authority
BG
Bulgaria
Prior art keywords
phenyl
diazepin
trifluoromethyl
oxo
dihydro
Prior art date
Application number
BG108253A
Other languages
Bulgarian (bg)
English (en)
Inventor
Geo Adam
Erwin Goetschi
Vincent Mutel
Juergen Wichmann
Johannes Woltering
Original Assignee
F.Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann - La Roche Ag filed Critical F.Hoffmann - La Roche Ag
Publication of BG108253A publication Critical patent/BG108253A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG108253A 2001-04-12 2003-10-10 ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I BG108253A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12

Publications (1)

Publication Number Publication Date
BG108253A true BG108253A (bg) 2005-03-31

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108253A BG108253A (bg) 2001-04-12 2003-10-10 ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I

Country Status (38)

Country Link
US (1) US6548495B2 (ja)
EP (1) EP1379522B1 (ja)
JP (1) JP4043953B2 (ja)
KR (1) KR100566178B1 (ja)
CN (1) CN1268626C (ja)
AR (1) AR035456A1 (ja)
AT (1) ATE287883T1 (ja)
AU (1) AU2002310912B2 (ja)
BG (1) BG108253A (ja)
BR (1) BR0208887A (ja)
CA (1) CA2441771C (ja)
CZ (1) CZ20033002A3 (ja)
DE (1) DE60202761T2 (ja)
DK (1) DK1379522T3 (ja)
EC (1) ECSP034796A (ja)
ES (1) ES2235044T3 (ja)
GT (1) GT200200072A (ja)
HK (1) HK1068339A1 (ja)
HR (1) HRP20030791B1 (ja)
HU (1) HUP0400991A3 (ja)
IL (2) IL158021A0 (ja)
JO (1) JO2273B1 (ja)
MA (1) MA27011A1 (ja)
MX (1) MXPA03009317A (ja)
MY (1) MY130369A (ja)
NO (1) NO325300B1 (ja)
NZ (1) NZ528345A (ja)
PA (1) PA8543201A1 (ja)
PE (1) PE20021072A1 (ja)
PL (1) PL367086A1 (ja)
PT (1) PT1379522E (ja)
RU (1) RU2270197C2 (ja)
SI (1) SI1379522T1 (ja)
SK (1) SK13692003A3 (ja)
UY (1) UY27259A1 (ja)
WO (1) WO2002083665A1 (ja)
YU (1) YU79103A (ja)
ZA (1) ZA200307242B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1224175T3 (da) * 1999-10-15 2004-07-12 Hoffmann La Roche Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
JP5005343B2 (ja) * 2003-07-25 2012-08-22 エフ.ホフマン−ラ ロシュ アーゲー 急性及び/又は慢性神経障害の治療のためのmGluR2アンタゴニストとAChEインヒビターの併用
ATE400557T1 (de) 2004-11-05 2008-07-15 Hoffmann La Roche Verfahren zur herstellung von isonikotinsäurederivaten
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2684760A1 (en) * 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
EP2205565B1 (en) * 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
AU2013336863A1 (en) 2012-10-23 2015-03-19 F. Hoffmann-La Roche Ag MGlu2/3 antagonists for the treatment of autistic disorders
UA114950C2 (uk) * 2013-02-28 2017-08-28 Ейсей Р Енд Д Менеджмент Ко., Лтд. ТЕТРАГІДРОІМІДАЗО[1,5-d][1,4]ОКСАЗЕПІНОВА ПОХІДНА
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1210338A2 (en) * 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
RU2259360C2 (ru) * 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Производные бензодиазепина и лекарственное средство, их содержащее
DK1224175T3 (da) * 1999-10-15 2004-07-12 Hoffmann La Roche Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister

Also Published As

Publication number Publication date
HUP0400991A3 (en) 2009-06-29
ES2235044T3 (es) 2005-07-01
RU2270197C2 (ru) 2006-02-20
UY27259A1 (es) 2002-10-31
YU79103A (sh) 2006-05-25
IL158021A (en) 2010-04-15
EP1379522A1 (en) 2004-01-14
SI1379522T1 (en) 2005-04-30
IL158021A0 (en) 2004-03-28
RU2003130648A (ru) 2005-04-10
ATE287883T1 (de) 2005-02-15
PL367086A1 (en) 2005-02-21
ZA200307242B (en) 2004-12-16
DK1379522T3 (da) 2005-05-30
CA2441771C (en) 2008-12-30
SK13692003A3 (sk) 2004-05-04
CZ20033002A3 (cs) 2004-03-17
NO325300B1 (no) 2008-03-25
GT200200072A (es) 2003-06-19
ECSP034796A (es) 2003-12-01
HRP20030791B1 (en) 2006-06-30
PA8543201A1 (es) 2002-10-31
JP4043953B2 (ja) 2008-02-06
WO2002083665A1 (en) 2002-10-24
NO20034496L (no) 2003-10-08
CA2441771A1 (en) 2002-10-24
JP2004525965A (ja) 2004-08-26
EP1379522B1 (en) 2005-01-26
US6548495B2 (en) 2003-04-15
NZ528345A (en) 2005-04-29
MXPA03009317A (es) 2004-02-12
HUP0400991A2 (hu) 2004-08-30
HRP20030791A2 (en) 2005-06-30
PT1379522E (pt) 2005-05-31
US20020198197A1 (en) 2002-12-26
CN1522252A (zh) 2004-08-18
KR20030088502A (ko) 2003-11-19
HK1068339A1 (en) 2005-04-29
MA27011A1 (fr) 2004-12-20
NO20034496D0 (no) 2003-10-08
BR0208887A (pt) 2004-06-29
MY130369A (en) 2007-06-29
CN1268626C (zh) 2006-08-09
AR035456A1 (es) 2004-05-26
PE20021072A1 (es) 2002-12-07
AU2002310912B2 (en) 2005-06-16
KR100566178B1 (ko) 2006-03-29
JO2273B1 (en) 2005-04-07
DE60202761T2 (de) 2006-01-12
DE60202761D1 (de) 2005-03-03

Similar Documents

Publication Publication Date Title
BG108253A (bg) ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I
EP1379511B1 (en) DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
AU2002310912A1 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I
ES2215738T3 (es) Derivados de benzodiazepina como receptor de glutamato metabotropico.
AU2002312788A1 (en) Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as mGluR2 antagonists II
CZ20021653A3 (cs) Nové deriváty benzodiazepinu
RU45093U1 (ru) Пылеуловитель